Barclays
ZNTL icon

Barclays’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Barclays’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$770K Sell
158,856
-432,361
-73% -$1.73M ﹤0.01% 2950
2026
Q1 		$1.38M Buy
591,217
+22,774
+4% +$58.8K ﹤0.01% 2558
2025
Q4 		$767K Buy
568,443
+406,973
+252% +$592K ﹤0.01% 3609
2025
Q3 		$244K Buy
161,470
+161,469
+16,146,900% +$242K ﹤0.01% 4206
2025
Q2 		$1 Sell
1
-59,615
-100% -$78.6K ﹤0.01% 5206
2025
Q1 		$94.8K Sell
59,616
-57,779
-49% -$125K ﹤0.01% 4429
2024
Q4 		$356K Buy
117,395
+42,000
+56% +$138K ﹤0.01% 4027
2024
Q3 		$277K Buy
75,395
+11,748
+18% +$42.7K ﹤0.01% 4131
2024
Q2 		$260K Sell
63,647
-2,670
-4% -$29.8K ﹤0.01% 3429
2024
Q1 		$1.05M Sell
66,317
-153,201
-70% -$2.11M ﹤0.01% 3088
2023
Q4 		$3.33M Buy
219,518
+108,701
+98% +$1.59M ﹤0.01% 2470
2023
Q3 		$2.22M Sell
110,817
-101,598
-48% -$2.58M ﹤0.01% 1831
2023
Q2 		$5.99M Buy
212,415
+122,451
+136% +$2.94M ﹤0.01% 1250
2023
Q1 		$1.55M Sell
89,964
-37,910
-30% -$768K ﹤0.01% 2398
2022
Q4 		$2.58M Buy
127,874
+11,276
+10% +$243K ﹤0.01% 2082
2022
Q3 		$2.53M Buy
116,598
+113,153
+3,285% +$3.09M ﹤0.01% 1592
2022
Q2 		$97K Sell
3,445
-3,409
-50% -$90.3K ﹤0.01% 3785
2022
Q1 		$316K Buy
+6,854
New +$370K ﹤0.01% 3183

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Barclays's ZNTL Position: Q2 2026 in Review

Barclays reduced its Zentalis Pharmaceuticals (ZNTL) stake by 73% in Q2 2026, selling an estimated $1.73M and leaving 158,856 shares worth $770K. The position accounts for ﹤0.01% of the portfolio, ranked #2950.

Barclays first reported a position in ZNTL in Q1 2022 and has held it in 18 quarters since. The position peaked at $5.99M in Q2 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Barclays held 158,856 shares of Zentalis Pharmaceuticals worth $770K as of Q2 2026.
  • Barclays sold 432,361 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $1.73M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2950 holding.
  • Barclays first reported a position in Zentalis Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Zentalis Pharmaceuticals position peaked at $5.99M in Q2 2023.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.